Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Spirapril

Подписчиков: 0, рейтинг: 0
Spirapril
Spirapril structure.svg
Clinical data
Trade names Renormax
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • D
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 50%
Metabolism converted to spiraprilat
Elimination half-life 30 to 35 hours
Excretion Hepatic and renal
Identifiers
  • (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C22H30N2O5S2
Molar mass 466.61 g·mol−1
3D model (JSmol)
  • O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3
  • InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1 checkY
  • Key:HRWCVUIFMSZDJS-SZMVWBNQSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Spirapril, sold under the brand name Renormax among others, is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.

It was patented in 1980 and approved for medical use in 1995.

Chemistry

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment. However, data on its effect upon the renal function are conflicting.

External links

  • Media related to Spirapril at Wikimedia Commons



Новое сообщение